Journal: BMJ Open

Article Title: Combined use of a broad-panel respiratory multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in patients with severe community-acquired pneumonia (MULTI-CAP): a multicentre, parallel-group, open-label, individual randomised trial conducted in French intensive care units

doi: 10.1136/bmjopen-2020-048187

Figure Lengend Snippet: Trial design. In the intervention arm, before the end of day 1, clinicians have to consider all the early microbiological results (mPCR FA-PPP, urine antigen assays, blood cultures and Gram stain examination of respiratory tract sample) and procalcitonin before the end of day 1, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation (red square). This algorithm is described in . In both arms, at day 3 and day after day until day 7, clinicians are encouraged to consider antibiotic discontinuation, based on procalcitonin values and kinetics. CAP, community-acquired pneumonia; FA-PPP, FilmArray Pneumonia Panel Plus; ICU, intensive care unit; mPCR, multiplex PCR.

Article Snippet: In the experimental strategy arm, the microbiological diagnosis combines a broad-panel respiratory mPCR (FilmArray Pneumonia Panel Plus (FA-PPP), BioFire Biomérieux) with conventional microbiological investigations.

Techniques: Staining, Multiplex Assay

Journal: BMJ Open

Article Title: Combined use of a broad-panel respiratory multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in patients with severe community-acquired pneumonia (MULTI-CAP): a multicentre, parallel-group, open-label, individual randomised trial conducted in French intensive care units

doi: 10.1136/bmjopen-2020-048187

Figure Lengend Snippet: Algorithm of early antibiotics de-escalation or discontinuation. The algorithm is applied in the intervention arm only (see red square, ). mPCR, multiplex PCR; ICU, intensive care unit; PCT, procalcitonin.

Article Snippet: In the experimental strategy arm, the microbiological diagnosis combines a broad-panel respiratory mPCR (FilmArray Pneumonia Panel Plus (FA-PPP), BioFire Biomérieux) with conventional microbiological investigations.

Techniques: Multiplex Assay

Journal: BMJ Open

Article Title: Combined use of a broad-panel respiratory multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in patients with severe community-acquired pneumonia (MULTI-CAP): a multicentre, parallel-group, open-label, individual randomised trial conducted in French intensive care units

doi: 10.1136/bmjopen-2020-048187

Figure Lengend Snippet: Primary and secondary outcomes

Article Snippet: In the experimental strategy arm, the microbiological diagnosis combines a broad-panel respiratory mPCR (FilmArray Pneumonia Panel Plus (FA-PPP), BioFire Biomérieux) with conventional microbiological investigations.

Techniques: Bacteria, Biomarker Discovery

Journal: Frontiers in Microbiology

Article Title: Laboratory Diagnosis of Respiratory Tract Infections in Children – the State of the Art

doi: 10.3389/fmicb.2018.02478

Figure Lengend Snippet: Commercially available nucleic acid amplification assays for respiratory pathogens a .

Article Snippet: FilmArray ® respiratory panel ® (RP) EZ , BioFire Diagnostics, Inc., , Nested multiplex RT-PCR , Multiplex Panel (14 targets) , NPS , ∼1 h , Waived.

Techniques: Amplification, Luminex, Quantitative RT-PCR, Multiplex Assay, Microarray, DNA Hybridization, Reverse Transcription Polymerase Chain Reaction, Hybridization, Virus, Real-time Polymerase Chain Reaction, DNA Amplification

Journal: Journal of Infection and Chemotherapy

Article Title: The impact analysis of a multiplex PCR respiratory panel for hospitalized pediatric respiratory infections in Japan ☆

doi: 10.1016/j.jiac.2019.07.014

Figure Lengend Snippet: Background.

Article Snippet: We replaced rapid antigen tests with the mPCR respiratory panel (FilmArray®; Biofire, Utah, USA) as a microbiological diagnostic test for pediatric respiratory infections admitted since March 26, 2018.

Techniques: Biomarker Discovery

Journal: Journal of Infection and Chemotherapy

Article Title: The impact analysis of a multiplex PCR respiratory panel for hospitalized pediatric respiratory infections in Japan ☆

doi: 10.1016/j.jiac.2019.07.014

Figure Lengend Snippet: mPCR group chart.

Article Snippet: We replaced rapid antigen tests with the mPCR respiratory panel (FilmArray®; Biofire, Utah, USA) as a microbiological diagnostic test for pediatric respiratory infections admitted since March 26, 2018.

Techniques:

Journal: Journal of Infection and Chemotherapy

Article Title: The impact analysis of a multiplex PCR respiratory panel for hospitalized pediatric respiratory infections in Japan ☆

doi: 10.1016/j.jiac.2019.07.014

Figure Lengend Snippet: Outcomes.

Article Snippet: We replaced rapid antigen tests with the mPCR respiratory panel (FilmArray®; Biofire, Utah, USA) as a microbiological diagnostic test for pediatric respiratory infections admitted since March 26, 2018.

Techniques:

Journal: Journal of Infection and Chemotherapy

Article Title: The impact analysis of a multiplex PCR respiratory panel for hospitalized pediatric respiratory infections in Japan ☆

doi: 10.1016/j.jiac.2019.07.014

Figure Lengend Snippet: The number of pathogen detections by mPCR. Adeno; Adenovirus, Corona; Coronavirus HKU1, NL63, 229E or OC43, hMPV; human metapneumovirus, Rhino/Entero; Rhinovirus or Enterovirus, Flu; Influenza virus A, A H1, A H3, A H1-2009 or B, RS; Respiratory syncytial virus, Para; Parainfluenza virus 1, 2, 3 or 4, Mycoplasma; Mycoplasma Pneumoniae , Chlamydia; Chlamydia Pneumoniae , Pertussis; Bordetella pertussis .

Article Snippet: We replaced rapid antigen tests with the mPCR respiratory panel (FilmArray®; Biofire, Utah, USA) as a microbiological diagnostic test for pediatric respiratory infections admitted since March 26, 2018.

Techniques: Virus

Journal: Canadian Respiratory Journal

Article Title: Impact of Nasopharyngeal FilmArray Respiratory Panel Results on Antimicrobial Decisions in Hospitalized Patients

doi: 10.1155/2018/9821426

Figure Lengend Snippet: Flow diagram depicting positive and negative NP-FARP cohorts with subsequent antibiotic decisions. NP-FARP, nasopharyngeal FilmArray respiratory panel.

Article Snippet: The nasopharyngeal FilmArray respiratory panel (NP-FARP) (BioFire Diagnostics, Salt Lake City, UT) was the first multiplex molecular panel approved in 2011 by the United States Food and Drug Administration for the detection of both bacterial and viral respiratory pathogens in nasopharyngeal swabs and was brought into our institution in February 2013.

Techniques: